Blizard Institute - Barts and The London

Dr William Alazawi, MA(Cantab) MB BChir PhD MRCP

William

Reader & Consultant in Hepatology

Email: w.alazawi@qmul.ac.uk
Telephone: 020 7882 7195

Profile

He conducted his doctorate research in Professor Coleman’s laboratory at the MRC Cancer Cell Unit and discovered that a dominant host response to viral integration is altered interferon responsiveness. He moved to London to work with Professor Foster and studied the role of STAT2 as a pivotal signalling mediator in TLR-mediated inflammation. He became an NIHR Clinical Lecturer in 2011 and has been funded by the Academy of Medical Sciences.  He held the prestigious Physician Scientist Fellowship of the European Association for the Liver 20134-2015 and currently holds a New Investigator Award from the Medical Research Council.

 

Clinical trials in non-alcoholic steatohepatitis

 

Collaborators

Professor Graham Foster (QMUL)

Professor Robert Goldin (Imperial College)

Professor Saheer Gharbia (Public Health England)

Dr Alastair O’Brien (UCL)

EMIF (European Medical Information Framework) network

Summary

Dr William Alazawi is a Reader and Consultant Hepatologist at Queen Mary, University of London and Bart’s Health NHS Trust.  He qualified from the MB/PhD Programme in Cambridge and trained at Addenbrooke’s, Hammersmith, Royal London and King’s College Hospitals. 

 

 

 

Teaching

 

Invited speaker for interdisciplinary training courses

Lecturer and examiner for undergraduate medicine

Lecturer on MSc courses in Gastroenterology & Critical Care

OSCE tutor

Medical student mentor

SSC supervisor

Project supervisor for SBCS and Intercalated BSc students

 


Research

Research Interests:

Death rates from liver disease are rising across the world, despite the fact that the leading causes of liver disease (non-alcoholic fatty liver disease (NAFLD), alcohol and chronic viral infections) are preventable or treatable.  Our understanding of the development of chronic liver diseases (regardless of the cause) is that persistent injury occurs alongside exaggerated or inappropriate inflammatory and repair responses. This leads to scarring or fibrosis and cirrhosis, which, in turn, can lead to liver failure and liver cancer.

The Alazawi group’s principal focus is the key early step in this process – inflammation. Our integrated research programme has a firm foundation in basic molecular and disease model discovery science, funded by the Medical Research Council. Our on-going translational projects utilise our expertise in inflammatory signalling to answer key clinical questions.  To directly impact clinical care, we are developing innovative approaches to delivering services in primary and secondary care.

Current Research Projects:

  1. The Role of STAT2 in Inflammation in the liver and pancreas
  2. Immune and inflammatory and microbiome profiling in patients with Non-Alcoholic Fatty Liver Disease
  3. Innate Immune and Inflammatory predictors of sepsis in patients undergoing surgery to the liver and pancreas.
  4. Population studies investigating risk factors for NAFLD and its complications
 

 

Publications

Improving prevention strategies for cardiometabolic disease. Sattar, N, Gill JMR, Alazawi, W. Nature Medicine 2020 26(3):320-325

Recorded diagnosis of NAFLD and the risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Dhalwani N, Kendrick S, Celis-Morales C, Waterworth DM, Alazawi W*, Sattar N*. *Joint Senior Authors. BMJ 2019 367:I5367

ADAM17-mediated reduction in CD14++CD16+ monocytes ex vivo and reduction in intermediate monocytes with immune paresis in acute pancreatitis and acute alcoholic hepatitis. Waller KJ, James C, de Jong A, Blackmore L, Ma Y, Stagg AJ, Kelsell D, O’Dwyer M, Alazawi W. Frontiers in Immunology. 2019 10:1902

Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Waterworth DM, Kendrick S, Sattar N, Alazawi W. BMC Medicine. 2019 May 20;17(1):95

Real world data reveal a diagnostic gap in non-alcoholic fatty liver disease. Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Kendrick S, Waterworth DM, Sattar N, Alazawi W. BMC Medicine 2018 16: 130.


View all William Alazawi's Research Publications at: http://www.researchpublications.qmul.ac.uk

Supervision

 

 
Dr Helen Heath PhD
Postdoctoral Researcher
 
Gary Britton
Postdoctoral Researcher
 
Ms Kathryn Waller
PhD Student
 
Mr Stephan Abdallah
BSc Student